Taysha Gene Therapies Inc Condensed Consolidated Balance Sheet Data in thousands except share and per share data Unaudited June 30 2023December 31 2022 ASSETS Current assets Cash and cash equivalents  45083 87880 Prepaid expenses and other current liabilities 9032 8537 Total current assets 54115 96417 Restricted cash 2637 2637 Property plant and equipment net 14139 14963 Operating lease rightofuse assets 10348 10943 Other noncurrent assets 304 1316 Total assets  81543 126276 LIABILITIES AND STOCKHOLDERS DEFICIT EQUITY Current liabilities Accounts payable  10766 10946 Accrued expenses and other current liabilities 19631 18287 Deferred revenue 26909 33557 Total current liabilities 50641 62790 Deferred revenue net of current portion 6212 Term loan net 38354 37967 Operating lease liability net of current portion 19528 20440 Other noncurrent liabilities 3922 4130 Total liabilities 118657 125327 Stockholders deficit equity Preferred stock 000001 par value per share 10000000 shares authorized and no shares issued and outstanding as of June 30 2023 and December 31 2022   Common stock 000001 par value per share 200000000 shares authorized and 64432637 and 63207507 issued and outstanding as of June 30 2023  and December 31 2022  respectively 1 1 Additional paidin capital 406546 402389 Accumulated deficit 443661 401441 Total stockholders deficit equity 37114 949 Total liabilities and stockholders deficit equity  81543 126276 Taysha Gene Therapies Inc Condensed Consolidated Statements of Operations in thousands except share and per share data Unaudited For the three months ended June 30 2023For the three months ended June 30 2022For the six months ended June 30 2023For the six months ended June 30 2022 Revenue Service Revenue  2395    7101   Operating expenses Research and development 19791 23506 32305 61688 General and administrative 5988 9867 14739 21336 Total operating expenses 25779 33373 47044 83024 Loss from operations 23384 33373 39943 83024 Other income expense Interest Income 223 27 542 41 Interest expense 1440 743 2814 1415 Other expense 3 3 5 11 Total other income expense 1214 719 2277 1385 Net loss  24598 34092 42220 84409 Net loss per common share basic and diluted  038 085 066 216 Weighted average common shares outstanding basic and diluted 64244531 40142403 63755435 39163996 Company Contact Hayleigh Collins Director Head of Corporate Communications Taysha Gene Therapies Inc hcollinstayshagtxcom Media Contact Carolyn Hawley Canale Communications carolynhawleycanalecommcom Source Taysha Gene Therapies Inc